Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
panina, Elena S
FORPE, NCT04688320: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase	Completed	3	310	RoW	Recombinant nonimmunogenic staphylokinase, Fortelyzin, Alteplase, Actillyze	Supergene, LLC	Massive Pulmonary Embolism	07/23	07/23
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Chirva, Tamara A
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Tavlueva, Evgenia V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28